PICARD MEDICAL, INC. Issues Letter to Shareholders
Picard Medical, Inc. reported significant progress in 2025 and early 2026, including revenue growth, improved gross margins, and successful debt reduction. The company is advancing its SynCardia Total Artificial Heart and developing the next-generation Emperor TAH, with clinical trials underway and potential FDA submissions planned. Efforts focus o…